Why daratumumab + VRd + cyclophosphamide might be an option to consider for high-risk NDMM?

Daratumumab in the treatment of MM with high-risk cytogeneticsПодробнее

VMP + Daratumumab for High-Risk Multiple MyelomaПодробнее

TOTAL Therapy 7: high response rates in high risk NDMM to daratumumabПодробнее

Drs. Shah, Kumar, & Lonial talk the latest in #MultipleMyeloma from #ASCO22 - https://bit.ly/3aBsAG9Подробнее

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent linesПодробнее

MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCLПодробнее

SQ daratumumab bortezomib cyclophosphamide dex in pts with newly diagnosed light chain amyloidosisПодробнее

Evaluation of Daratumumab for the Treatment of Multiple MyelomaПодробнее

Daratumumab, Carfilzomib, Lenalidomide & Dexamethasone w/ MRD Res. Adapted Therapy in Newly Diag. MMПодробнее

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone...Подробнее

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MMПодробнее

Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogene...Подробнее

Getting Clear Answers to Complex Treatment Challlenges in Multiple MyelomaПодробнее

Changing Perspectives on Multiple Myeloma and ASCTПодробнее

New Strategies for Multiple Myeloma Care: Next Steps for the FutureПодробнее

Daratumumab and isatuximab in the treatment of multiple myelomaПодробнее

Cassiopeia: analysis of daratumumab maintenance for myelomaПодробнее

B-PRISM: Phase II trial of Dara-VRd in high-risk smoldering multiple myelomaПодробнее

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in ...Подробнее